Goldman Sachs’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $33.1M | Buy |
2,937,367
+503,981
| +21% | +$5.68M | ﹤0.01% | 1411 |
|
|
2025
Q1 | $24.6M | Buy |
2,433,386
+324,764
| +15% | +$3.28M | ﹤0.01% | 1551 |
|
|
2024
Q4 | $24.9M | Sell |
2,108,622
-3,283,753
| -61% | -$38.8M | ﹤0.01% | 1593 |
|
|
2024
Q3 | $62.2M | Buy |
5,392,375
+1,191,040
| +28% | +$13.7M | 0.01% | 922 |
|
|
2024
Q2 | $44.4M | Buy |
4,201,335
+2,702,419
| +180% | +$28.6M | 0.01% | 1062 |
|
|
2024
Q1 | $15.8M | Buy |
1,498,916
+1,085,821
| +263% | +$11.4M | ﹤0.01% | 1701 |
|
|
2023
Q4 | $4.64M | Buy |
413,095
+170,966
| +71% | +$1.92M | ﹤0.01% | 2647 |
|
|
2023
Q3 | $2.83M | Buy |
242,129
+142,981
| +144% | +$1.67M | ﹤0.01% | 2868 |
|
|
2023
Q2 | $999K | Sell |
99,148
-1,676,043
| -94% | -$16.9M | ﹤0.01% | 3605 |
|
|
2023
Q1 | $13.1M | Buy |
1,775,191
+1,253,849
| +241% | +$9.25M | ﹤0.01% | 1811 |
|
|
2022
Q4 | $4.17M | Buy |
521,342
+322,742
| +163% | +$2.58M | ﹤0.01% | 2756 |
|
|
2022
Q3 | $639K | Sell |
198,600
-2,680
| -1% | -$8.62K | ﹤0.01% | 4094 |
|
|
2022
Q2 | $819K | Buy |
201,280
+181,089
| +897% | +$737K | ﹤0.01% | 4087 |
|
|
2022
Q1 | $100K | Buy |
+20,191
| New | +$100K | ﹤0.01% | 5314 |
|